Literature DB >> 26847743

Nuclear accumulation of myocyte muscle LIM protein is regulated by heme oxygenase 1 and correlates with cardiac function in the transition to failure.

Anju Paudyal1, Sukriti Dewan2, Cindy Ikie1, Benjamin J Whalley3, Pieter P de Tombe2, Samuel Y Boateng1.   

Abstract

KEY POINTS: The present study investigated the mechanism associated with impaired cardiac mechanosensing that leads to heart failure by examining the factors regulating muscle LIM protein subcellular distribution in myocytes. In myocytes, muscle LIM protein subcellular distribution is regulated by cell contractility rather than passive stretch via heme oxygenase-1 and histone deacetylase signalling. The result of the present study provide new insights into mechanotransduction in cardiac myocytes. Myocyte mechanosensitivity, as indicated by the muscle LIM protein ratio, is also correlated with cardiac function in the transition to failure in a guinea-pig model of disease. This shows that the loss mechanosensitivity plays an important role during the transition to failure in the heart. The present study provides the first indication that mechanosensing could be modified pharmacologically during the transition to heart failure. ABSTRACT: Impaired mechanosensing leads to heart failure and a decreased ratio of cytoplasmic to nuclear CSRP3/muscle LIM protein (MLP ratio) is associated with a loss of mechanosensitivity. In the present study, we tested whether passive or active stress/strain was important in modulating the MLP ratio and determined whether this correlated with heart function during the transition to failure. We exposed cultured neonatal rat myocytes to a 10% cyclic mechanical stretch at 1 Hz, or electrically paced myocytes at 6.8 V (1 Hz) for 48 h. The MLP ratio decreased by 50% (P < 0.05, n = 4) only in response to electrical pacing, suggesting impaired mechanosensitivity. Inhibition of contractility with 10 μm blebbistatin resulted in an ∼3-fold increase in the MLP ratio (n = 8, P < 0.05), indicating that myocyte contractility regulates nuclear MLP. Inhibition of histone deacetylase (HDAC) signalling with trichostatin A increased nuclear MLP following passive stretch, suggesting that HDACs block MLP nuclear accumulation. Inhibition of heme oxygenase1 (HO-1) activity with protoporphyrin IX zinc(II) blocked MLP nuclear accumulation. To examine how mechanosensitivity changes during the transition to heart failure, we studied a guinea-pig model of angiotensin II infusion (400 ng kg(-1)  min(-1) ) over 12 weeks. Using subcellular fractionation, we showed that the MLP ratio increased by 88% (n = 4, P < 0.01) during compensated hypertrophy but decreased significantly during heart failure (P < 0.001, n = 4). The MLP ratio correlated significantly with the E/A ratio (r = 0.71, P < 0.01, n = 12), a clinical measure of diastolic function. These data indicate for the first time that myocyte mechanosensitivity as indicated by the MLP ratio is regulated primarily by myocyte contractility via HO-1 and HDAC signalling.
© 2016 The Authors. The Journal of Physiology © 2016 The Physiological Society.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26847743      PMCID: PMC4908012          DOI: 10.1113/JP271809

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  28 in total

1.  Induction of the skeletal alpha-actin gene in alpha 1-adrenoceptor-mediated hypertrophy of rat cardiac myocytes.

Authors:  N H Bishopric; P C Simpson; C P Ordahl
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

Review 2.  Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling.

Authors:  Gerald W Dorn
Journal:  Cardiovasc Res       Date:  2008-09-08       Impact factor: 10.787

Review 3.  The role of the cardiac renin-angiotensin system in load-induced cardiac hypertrophy.

Authors:  J Sadoshima; R Malhotra; S Izumo
Journal:  J Card Fail       Date:  1996-12       Impact factor: 5.712

4.  2,3-Butanedione monoxime cardioplegia: advantages over hyperkalemia in blood-perfused isolated hearts.

Authors:  A M Jayawant; E R Stephenson; R J Damiano
Journal:  Ann Thorac Surg       Date:  1999-03       Impact factor: 4.330

5.  Transition from compensated hypertrophy to intrinsic myocardial dysfunction during development of left ventricular pressure-overload hypertrophy in conscious sheep. Systolic dysfunction precedes diastolic dysfunction.

Authors:  T Aoyagi; A M Fujii; M F Flanagan; L W Arnold; K W Brathwaite; S D Colan; I Mirsky
Journal:  Circulation       Date:  1993-11       Impact factor: 29.690

6.  Heme oxygenase-1 inhibits angiotensin II-induced cardiac hypertrophy in vitro and in vivo.

Authors:  Chien-Ming Hu; Yen-Hui Chen; Ming-Tsai Chiang; Lee-Young Chau
Journal:  Circulation       Date:  2004-06-28       Impact factor: 29.690

Review 7.  Mechano-signaling in heart failure.

Authors:  Byambajav Buyandelger; Catherine Mansfield; Ralph Knöll
Journal:  Pflugers Arch       Date:  2014-02-16       Impact factor: 3.657

8.  Alpha-skeletal muscle actin mRNA's accumulate in hypertrophied adult rat hearts.

Authors:  K Schwartz; D de la Bastie; P Bouveret; P Oliviéro; S Alonso; M Buckingham
Journal:  Circ Res       Date:  1986-11       Impact factor: 17.367

9.  Up-regulation of heme oxygenase-1 expression through CaMKII-ERK1/2-Nrf2 signaling mediates the anti-inflammatory effect of bisdemethoxycurcumin in LPS-stimulated macrophages.

Authors:  An Na Kim; Woo-Kwang Jeon; Jung Jun Lee; Byung-Chul Kim
Journal:  Free Radic Biol Med       Date:  2010-04-26       Impact factor: 7.376

10.  Neuronal expression of muscle LIM protein in postnatal retinae of rodents.

Authors:  Evgeny Levin; Marco Leibinger; Anastasia Andreadaki; Dietmar Fischer
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

View more
  9 in total

1.  Subcellular localization and function of 2LIM proteins in plants and humans.

Authors:  Céline Hoffmann; Josh Brown-Clay; Clément Thomas
Journal:  Planta       Date:  2017-10-09       Impact factor: 4.116

2.  Cysteine- and glycine-rich protein 3 regulates glucose homeostasis in skeletal muscle.

Authors:  Angelina Hernandez-Carretero; Natalie Weber; Samuel A LaBarge; Veronika Peterka; Nhu Y Thi Doan; Simon Schenk; Olivia Osborn
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-04-10       Impact factor: 4.310

3.  The role of muscle LIM protein in the nervous system.

Authors:  Daniel Terheyden-Keighley; Dietmar Fischer
Journal:  Neural Regen Res       Date:  2019-11       Impact factor: 5.135

Review 4.  Mix and (mis-)match - The mechanosensing machinery in the changing environment of the developing, healthy adult and diseased heart.

Authors:  Matthew Ward; Thomas Iskratsch
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2019-02-08       Impact factor: 4.739

5.  Effects of High-Fat Diet Induced Obesity and Fructooligosaccharide Supplementation on Cardiac Protein Expression.

Authors:  Sidra Sarfaraz; Shamjeet Singh; Aileen Hawke; Sandra T Clarke; D Dan Ramdath
Journal:  Nutrients       Date:  2020-11-05       Impact factor: 5.717

Review 6.  Epigenetics and Heart Failure.

Authors:  Syeda Shegufta Ameer; Mohammad Bakhtiar Hossain; Ralph Knöll
Journal:  Int J Mol Sci       Date:  2020-11-27       Impact factor: 5.923

Review 7.  Role of Muscle LIM Protein in Mechanotransduction Process.

Authors:  Philippe Germain; Anthony Delalande; Chantal Pichon
Journal:  Int J Mol Sci       Date:  2022-08-29       Impact factor: 6.208

8.  The exon junction complex senses energetic stress and regulates contractility and cell architecture in cardiac myocytes.

Authors:  Olivier A Pierrat; Anju Paudyal; James Woodruff; Olga Koroleva; Samuel Y Boateng
Journal:  Biosci Rep       Date:  2017-07-07       Impact factor: 3.840

9.  Generation of desminopathy in rats using CRISPR-Cas9.

Authors:  Henning T Langer; Agata A Mossakowski; Brandon J Willis; Kristin N Grimsrud; Joshua A Wood; Kevin C K Lloyd; Hermann Zbinden-Foncea; Keith Baar
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-09-07       Impact factor: 12.910

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.